Articles tagged with Cancer Patients
USC researchers will use $18.5 million funding to study colorectal cancer in Hispanic patients, aiming to close the gap in understanding the disease and developing effective treatments. The project aims to improve patient engagement in genomic research and develop culturally relevant educational materials.
Researchers investigated geographic disparities in initial breast cancer care, finding significant regional variations and unequal distribution of resources. The study suggests that both patient-level factors and regional characteristics contribute to these disparities, affecting treatment outcomes.
Sophie Paczesny's research aims to validate biomarker panels that help doctors predict chronic GVHD risk and adjust immune suppression treatments accordingly. The study uses machine learning algorithms to analyze stored plasma and blood cell samples from over 1,300 BMT recipients.
A study by Mayo Clinic researchers found that cancer patients receiving chemotherapy and targeted therapies may mount inadequate immune responses to COVID-19 vaccination. The authors recommend antibody level testing and booster vaccinations for these patients.
Researchers found that glioma cells with mutated ATRX have reduced Chk1 activity, leading to dysregulated cell cycle and heightened sensitivity to ATM inhibitors. The study suggests that combining radiation therapy with these inhibitors may improve treatment outcomes for patients with this gene mutation.
Four MUSC Hollings Cancer Center researchers received American Cancer Society Institutional Research Grants worth $35,000 each. The grants support promising projects that aim to push cancer care forward. Researchers are working on various innovative projects, including a digital literacy training program for community health workers an...
A new study published in Mayo Clinic Proceedings found that direct oral anticoagulants significantly decrease cancer-associated venous thrombosis recurrence without increasing bleeding. The study involved 2,894 patients and showed a 41% decrease in thrombosis recurrence with direct oral anticoagulants compared to parenteral dalteparin.
A meta-analysis published in The Lancet Oncology reveals that men with intermediate- and high-risk prostate cancer experience improved overall survival with the addition of hormone therapy to radiotherapy. The study found prolonged adjuvant hormone therapy benefits men, while neoadjuvant hormone therapy did not.
A study investigated the common use of extended radiation therapy for patients with metastatic cancer nearing the end of life. Despite guidelines advising against this practice, researchers found that it is still used in many cases. The study aims to shed light on this treatment approach and its implications for patient care.
A new combination immune therapy treatment extends cancer patients' lives while reducing toxic side effects and improving their overall health. This study found that the treatment was less toxic than other drugs on the market, providing an added benefit for patients' quality of life.
The NRG Oncology GOG 0261 trial demonstrated that paclitaxel and carboplatin is a non-inferior alternative to paclitaxel and ifosfamide for treating women with uterine carcinosarcoma. This regimen offers improved progression-free survival and overall survival compared to the current standard of care.
The first-in-human trial of CAR-M cell therapy demonstrated that engineered macrophages can target and alter the solid tumor microenvironment, altering the composition of myeloid cells and T-cells. This innovative immunotherapy offers a promising new strategy in the fight against cancer.
The study investigated the antibody response to 2 or 3 doses of the BioNTech-Pfizer vaccine in patients with solid tumors treated with anticancer agents. The researchers found that higher antibody levels were associated with better immune response and reduced risk of severe COVID-19.
A new study by Georgia Tech researchers has found a novel pathway for understanding why debilitating side effects occur with cancer treatment. The findings suggest that the central nervous system is vulnerable to cancer treatment's adverse effects, and correcting any one may not be enough to improve human function and quality of life.
Researchers found that 48% of patients experienced complete or partial response to pembrolizumab treatment, with two-thirds experiencing clinical response. The study suggests a potential for curative intent in patients with recurrent or metastatic uterine cancer.
A recent study found that three out of four patients with metastatic colorectal cancer experienced major financial hardship within 12 months of diagnosis, despite having access to health insurance. The study also showed a link between financial hardship and decreased quality of life and social functioning.
Researchers discovered that aberrant splicing of CD22 mRNA leads to decreased protein expression in pediatric B-lymphoblastic leukemia cells. This results in resistance to CD22-directed immunotherapies, making it challenging for oncologists to identify patients who may not respond to these treatments.
A Kaiser Permanente study shows that well-designed depression screening programs can effectively identify patients in need of behavioral health care and increase referrals. The program was successfully integrated into the patient care workflow of medical oncology teams, leading to improved mental health care for breast cancer patients.
A study of fully vaccinated patients with cancer who experienced breakthrough COVID-19 found a 13% mortality rate. Fully vaccinated patients were at high risk for hospitalization and death, even after receiving booster vaccines.
A high-fiber diet has been shown to improve the response of melanoma patients to immunotherapy by influencing the gut microbiome. Patients who consumed at least 20 grams of dietary fiber per day lived longer without their cancer progressing, compared to those who consumed less fiber.
A new post-surgery approach for treating HPV-related throat cancer uses low-dose radiation and spares the majority of patients from chemotherapy. The trial found high survival rates and quality of life in patients at medium risk for recurrence.
A recent study found that a substantial decline in lung cancer deaths is associated with earlier diagnosis of lung cancer through increased screening via computed tomography (CT) and follow-up scans. This approach can lead to surgical interventions, which can often be curative for precancerous nodules.
Researchers are part of a five-year global study examining the behavioral and long-term health impacts of different regulatory approaches to e-cigarettes and other new nicotine products among youth and adults in seven countries. The study aims to inform US public policy based on evidence, maximizing population health.
A new study warns that Omicron could lead to 100,273 fewer elective operations performed over the three winter months due to increased hospital admissions and COVID-19 patients. The model used NHS England data from September 2020 to July 2021 to project elective surgery activity based on the number of COVID-19 patients in hospital.
A recent study has identified a new mechanism by which oral cancer cells acquire radioresistance through the transfer of microRNA, specifically miR-503-3p. This discovery brings hope for the development of new treatments for radiation-resistant oral cancer.
A recent study published in JNCCN found that 33 out of 81 studies lacked transparency on censoring, which can introduce bias and affect trial results. The researchers emphasize the need for improved transparency and reporting in clinical trials to ensure patients and clinicians make informed decisions.
The KEYNOTE-811 trial demonstrates a significant improvement in objective response rate (74.4%) and tumor size reduction compared to trastuzumab and chemotherapy. The combination of pembrolizumab, trastuzumab, and chemotherapy markedly reduces tumor size and induces complete responses in some patients.
Researchers have discovered that a common class of targeted therapies can help more colorectal cancer patients than previously thought. By analyzing cell studies and computer modeling, the team identified 10 distinct RAS mutations that do not preclude the use of EGFR inhibitors, which are already approved for other uses.
A Phase 2 clinical trial showed sotorasib can shrink tumors and achieve disease control in heavily pretreated patients with advanced colorectal cancer. The study results exceeded the historic benefits linked to approved therapies, offering new hope for a population with limited treatment options.
A study found that rural women are less likely to get screened for colorectal cancer compared to urban counterparts, despite similar breast cancer screening rates. The disparity may be attributed to limited access to testing and financial constraints, highlighting the need for targeted public health interventions.
Researchers have discovered that NOR-1 protein can provide broad protection against heart damage following cancer treatment. Administering the protein directly may reduce heart risk, at least in laboratory tests.
A new treatment combination of dasatinib, blinatumomab, and prednisone has shown promise in treating older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. The trial achieved a three-year DFS rate of 80 percent and an overall survival rate of 85 percent for enrolled patients.
Surgeons at Henry Ford Health performed the world's first precision prostatectomy through the bladder using a single port robotic surgical system. The procedure preserves a portion of the prostate capsule, improving functional outcomes such as erectile function and urinary control.
Researchers found a novel therapy called AVID200 safe and well-tolerated, with modest improvements in symptom burden, anemia, and spleen enlargement. The therapy needs to be combined with other drugs to optimize impact in patients.
A team developed statistical models to predict the risk of early death in patients with non-intensive AML therapy. The models incorporated various health measures and quality-of-life scores, showing modest success in predicting outcomes.
A new NRG Oncology clinical trial found that bupropion did not improve sexual desire in female cancer survivors. The trial evaluated the effects of extended-release bupropion on postmenopausal women with low baseline sexual desire scores.
Research reveals tamoxifen boosts PI3K signaling, potentially increasing uterine cancer risk in breast cancer patients. Preclinical studies show PI3K inhibitor alpelisib mitigates this effect.
Researchers discovered that the SET2,3 index provides complementary prognostic information about breast cancer outcomes, particularly for patients with hormone receptor-positive breast cancer. The study suggests that using both clinical and molecular information from a patient's tumor can guide treatment decision-making.
Investigators at Weill Cornell Medicine identified significant age-related differences in tumor characteristics across various cancers, suggesting potential for personalized treatment approaches. They found that tumors from younger patients showed advanced signs of aging and more mutations associated with aggressive disease.
A recent study by NTU Singapore and Singapore General Hospital found that mutations in the DDX3X gene are responsible for chemotherapy resistance in some blood cancer patients. The study also discovered that STAT inhibitors can effectively kill lymphoma cells with DDX3X mutations, providing hope for new treatment options.
A new protein variant called CLIP-170S allows cancer cells to dodge chemotherapy drugs, rendering them ineffective. Researchers discovered this variant in more than 60% of patients with gastric cancer and are exploring a combination therapy involving imatinib to overcome resistance.
A University of Gothenburg study found that bariatric surgery lowers cancer risk by 60% in obese patients with type 2 diabetes, particularly those achieving and maintaining normal glucose control. The research highlights the importance of glucose control in preventing cancer in this high-risk population.
Researchers at Case Western Reserve University are developing an AI tool to analyze medical images and determine which rectal cancer patients require surgery. By using radiomics and machine learning techniques, the team hopes to identify patients who can avoid invasive surgery and opt for chemotherapy or radiation therapy instead.
A new study found that bowel cancer patients are at high risk of clinical levels of depression, with over a third experiencing symptoms up to five years after surgery. The study identified risk factors such as pre-existing depression and anxiety, low social support, and poor health.
A study found that COVID-19 vaccination significantly lowers the risk of SARS-CoV-2 infection among patients with cancer. The vaccinated group had a lower incidence of COVID-19 compared to those who did not receive the vaccine.
A research team developed an AI framework that analyzes protein interactions to predict effective and low-toxicity cancer drug combinations. The framework, GraphSynergy, outperforms conventional models in identifying synergistic combinations.
The FDA has approved Cytalux, which enables surgeons to identify and remove cancerous lesions with greater precision. In a Phase 3 study, nearly 27% of women with confirmed ovarian cancer found at least one undetected lesion during surgery.
A new diagnostic tool for breast cancer uses a low-voltage electrical current to detect changes in lymphatic interstitial fluid, showing 70% effectiveness in predicting cancer presence. The device can be used repeatedly on women of any age, providing an additional diagnostic option for younger patients and those with dense breast tissue.
Researchers analyzed data from 2016 to 2020 and found no significant difference in new cancer diagnoses among Canadian children during the pandemic. The study suggests that cancer diagnosis rates were not delayed, unlike previous reports suggesting a decline.
The study evaluated outcomes of minimally invasive esophagectomy compared to open esophagectomy in 6000 ESCC patients over 10 years. MIE was found to be an effective treatment option even for large tumors, expanding its indicated population.
CNIO researchers have identified a new biomarker for early melanoma metastasis, proposing the use of NGFR to predict disease prognosis and define risk groups. Blocking NGFR drastically reduces metastasis in mice, paving the way for a potential first treatment to tackle metastasis in its earliest stages.
Research found that proton pump inhibitors (PPIs) may reduce the effectiveness of immune checkpoint inhibitor drugs in patients with non-small-cell lung cancer. PPI use was associated with worse survival rates and a significant decrease in the benefit of immune therapy treatment.
Researchers at Karolinska Institutet found that certain bacteria from the digestive system can cause damage to pancreatic cells, increasing the risk of malignant tumours. The study suggests that antibiotics could prevent this damage, offering a potential prophylactic intervention.
A registry-based study of 2,600 patients in six European countries reveals a significant increase in COVID-19 mortality among cancer patients during the pandemic. The study suggests that cancer patients are at higher risk of severe illness and death from COVID-19 due to underlying health conditions.
Researchers found that second-generation antihistamines block histamine binding to HRH1, improving cytotoxic T cell activation and reducing resistance to immunotherapy. High plasma histamine levels in patients were correlated with worse responses to anti-PD-1 immunotherapy.
Researchers found that antihistamines improve responses to immune checkpoint inhibitors in cancer patients, particularly those with pre-existing allergies or high plasma histamine levels. The study suggests targeting the histamine receptor HRH1 may be a useful treatment approach.
Early antiretroviral therapy reduces skin and mucosal cancers in HIV patients by preserving tissue-resident memory T cells. Prompt treatment also improves the immune response, reducing the risk of HPV-associated cancers.
Despite increases in inclusion, certain groups remain under-represented in cancer clinical trials. Black and Hispanic patients showed improved participation, while women and older adults continued to be under-represented.
Researchers from the University of Copenhagen have discovered a natural substance, a flavonoid, that can inhibit cancer cells' ability to defend themselves against chemotherapy by targeting efflux pumps. This could lead to more effective treatment and potentially even combat antibiotic resistance.
Researchers found that higher lymphoma volume at diagnosis was associated with increased risk of recurrence. This could lead to improved patient outcomes by selecting the most appropriate treatment. The study also explored PET-based measures of initial disease burden, which may help predict patients' risk of recurrence.